Vol. 11, Issue 3 (2025)

Background: Osteoarthritis (OA) is one of the most prevalent degenerative joint disorders globally, characterized by progressive cartilage breakdown, subchondral bone remodelling, and chronic inflammation, leading to pain, stiffness, and impaired mobility. Despite its high burden, there are currently no approved disease-modifying therapies for OA. Conventional pharmacological options, such as NSAIDs and analgesics, offer symptomatic relief but are often associated with long-term safety concerns. This has prompted growing interest in evidence-based nutraceuticals that offer anti-inflammatory, antioxidant, and chondroprotective benefits with better tolerability. CollaFlex® PRO+, a combination of UC-II®, Mobilee®, and curcumin, is designed to address the multifactorial pathophysiology of OA through immune modulation, joint lubrication, and oxidative stress reduction.
Objective: To evaluate real-world clinical experience and perceptions of orthopedic specialists regarding the effectiveness, safety, and patient outcomes associated with CollaFlex® PRO+, in OA management.
Methods: A cross-sectional survey was conducted among 355 orthopedicians across India. The survey collected data on prescribing patterns, OA severity grades treated, treatment duration, observed clinical outcomes, safety profile, and overall willingness to recommend CollaFlex Pro+.
Results: CollaFlex® PRO+, was primarily prescribed for Grade II (45.74%) and Grade III (36.52%) OA. Most orthopedicians (76.58%) recommended a 3-month treatment duration. Regarding efficacy, 85.07% of orthopedicians rated CollaFlex® PRO+, as effective to highly effective for pain relief, and 85.11% for mobility improvement. Nearly all orthopedicians (95.99%) reported noticeable patient improvements, particularly in mobility, flexibility, and stiffness reduction. The product was well tolerated, with 95.71% of orthopedicians reporting no adverse events, only mild gastrointestinal disturbances were noted in a few cases. The key driver for adoption was the “Right Dose, Right Combination” (68.46%), and 97.71% expressed willingness to recommend the product to peer
Conclusion: The survey highlights strong clinical confidence in CollaFlex® PRO+, as a safe and effective nutraceutical for managing mild to moderate OA. Its favorable tolerability, patient-reported benefits, and evidence-backed formulation make it a valuable adjunct in long- term OA care.